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Abstract 
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that involves a devastating 
clinical course and lacks an effective treatment.  A biochemical model for neuronal development, 
recently proposed by Nikolaev and co-workers, hinges on a novel protein-protein interaction 
between the death cell receptor six (DR6) ectodomain and an N-terminal fragment of amyloid 
precursor protein (NAPP). The model provides a coherent and satisfying framework for better 
understanding AD pathophysiology. Moreover, the DR6-NAPP interaction offers a tempting 
target for novel pharmacological intervention. Given all of this, we constructed a structural 
model of the DR6-NAPP interaction using the neurotrophin p75 receptor as a template. 
Importantly, crucial steps in the modeling pipeline were independently validated using the p75 
receptor. The final docked model shows excellent agreement with a variety of biophysical and 
theoretical data sets.  Particularly worth noting is the excellent observed agreement between the 
theoretically calculated DR6-NAPP binding free energy and the corresponding experimental 
quantity.  In brief, the balance of the evidence suggests that the DR6-NAPP model proposed here 
should prove useful in future studies, modeling work and efforts aimed at structure-based drug 
design. 
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Introduction 
 Alzheimer’s disease (AD) is the sixth leading cause of death in the United States.  
Currently, an estimated 5.3 million Americans of all ages have the disease1.  Alzheimer’s disease 
is a neurodegenerative disorder that is pathologically defined by the presence of amyloid 
depositions and neurofibrillary tangles.  The AD brain is further characterized by neuronal loss, 
primarily in the cerebral cortex and hippocampus, and cholinergic depletion.  Clinically, AD 
follows a progressive course marked by cognitive impairment and memory loss2-4.   Despite 
several decades of research, a cure for Alzheimer's disease does not exist; available treatments 
offer relatively small symptomatic benefit and remain palliative in nature.   
     Most experts agree that the amyloid precursor protein (APP) and APP proteolysis play a role 
in AD.  Similarly, the evidence seems to implicate neuronal loss, neuronal degeneration and 
axonal degeneration in the progression of disease.  The available evidence also indicates a role 
for apoptosis in the pathophysiology of Alzheimer’s disease and for pro-apoptotic caspase 
enzymes in particular.  Indeed, it has been hypothesized that caspase-6 plays a key role in disease 
propagation2,4-8. 
     A growing body of evidence indicates an important role for trophic factor deprivation, 
specifically nerve growth factor (NGF) and brain-derived nerve growth factor (BDNF) 
deprivation, in the etiology and pathophysiology of Alzheimer’s disease.  A particularly striking 
example of this includes the development of a mouse model (AD11 anti-NGF mice) that 
expresses transgenic NGF antibodies and that is marked by progressive neurodegeneration, 
amyloid deposition, neurofibrillary tangles, cholinergic depletion, and behavioral deficits.  The 
role of NGF deprivation is further underscored by the successful use NGF supplementation to 
rescue AD11 mice and by a recent study which suggests the efficacy of NGF therapy for 
reversing neuronal cholinergic decline in aged, non-human primates2,9-11. 
     Clearly, the elucidation of a biochemical mechanism that connects all of the data, especially 
trophic factor deprivation, altered APP metabolism, caspase activation, neuronal apoptosis and 
neuritic degeneration, would help to improve our understanding of the cellular events that 
underlie AD and suggest new and promising routes for novel therapeutic development.  Hints of 
such a biochemical mechanism come from a recent study that correlates NGF and BDNF 
withdrawal, neurotrophin receptor p75 activity, amyloidogenesis, and apoptosis in hippocampal 
neurons12.  A still more recent study, published by Nikolaev and co-workers, suggests a new 
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biochemical model for AD that accounts for the data of the previously mentioned study and that 
also includes an explicit role for caspase-3 and caspases-6 in mediating apoptotic neuronal 
degeneration and axonal degeneration, respectively.  The model suggested by Nikolaev and co-
workers, however, introduces a new protein into the story termed death cell receptor 6 (DR6), a 
trasmembrane receptor with an intracellular death domain that appears to be activated by an N-
terminal APP fragment (NAPP)13. 
     The primary focus of the Nikolaev et al. paper was the elucidation of a novel molecular 
mechanism to account for axonal pruning and neuronal cell death during physiological 
development.  According to the developmental model proposed by Nikolaev et al, tropic factor 
deprivation results in APP proteolysis, culminating in the release of an N-terminal APP fragment 
(NAPP) into the extracellular milieu.  NAPP then serves as a ligand for DR6 and activates DR6.  
Activation of DR6 results in the subsequent downstream activation of caspase3 and caspase6, 
respectively, resulting in accelerated neuronal apoptosis, neuronal degeneration, axonal 
degeneration and the physiological sculpting of nerve connections in the developing brain.  
Nikolaev and co-workers suggested that this physiological pathway could be hijacked in the 
adult brain, possibly resulting in AD.  
     Hence, the AD model proposed by Nikolaev and co-workers explicitly links trophic factor 
deprivation with neuronal loss and degeneration through a series of well characterized 
biomolecular events that might be susceptible to therapeutic intervention.  In particular, the 
model proposed by Nikolaev and co-workers suggests an obvious opportunity for innovative 
therapeutic intervention in the form of rationally designed molecular inhibitors of the NAPP-
DR6 protein-protein interaction.  Such a therapeutic approach could be used as an alternative or 
supplement to NGF therapy and other therapeutic modalities.  Moreover, the NAPP-DR6 
interaction has the advantage of being an upstream event and there is growing interest in the 
rational design of therapeutic protein-protein modulators14. 
     The rational design of molecular antagonists of the DR6-NAPP interaction would clearly 
benefit from an atomic-level or residue-level structural model of the DR6-NAPP complex.  
Similarly, our collective theoretical understanding of the interaction and our ability to design and 
interpret experiments would also benefit from a structural model.  Unfortunately, such a 
molecular model is lacking.  Indeed, while a monomeric crystal structure of the growth factor 
like domain of NAPP is available (GFD NAPP), a monomeric structure of the DR6 ectodomain 
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is not15.  Importantly, Nikolaev and co-workers performed an experiment using an antibody 
specific for the growth factor like domain (GFD) of NAPP (anti-GFD NAPP (22C11)) that 
blocked DR6 binding, a result which suggests a key role for GFD mediated binding to DR6. 
     Given all of this, we hypothesized that GFD NAPP forms a stable interaction with DR6 and 
labored to produce a theoretical model of the DR6- GFD NAPP interaction through the use of 
advanced homology modeling, docking, energy minimization and binding free energy 
calculations.  More specifically, we used I-TASSER and implicit solvent energy minimization to 
build and refine a homology model of the DR6 ectodomain16-22.  We then used the ClusPro rigid-
body docking server to dock the DR6 model to the crystal structure of GFD NAPP23,24.  This was 
followed by rigid-body energy minimization, implicit solvent pseudo-free energy scoring and 
final scoring and ranking using a recently described empirical free energy function25-27.  The 
final model was verified against the available biophysical data, including a novel theoretical data 
set that was generated using a second and independent computational procedure for predicting 
protein-protein interface residues.  Perhaps most importantly, the theoretical binding affinity 
implied by our DR6-GFD NAPP model is shown to be in quantitative agreement with the 
experimentally determined binding affinity measured by Nikolaev and co-workers.  To the best 
of our knowledge, such quantitative free energy testing represents a milestone in theoretical 
model construction and testing.  Based on extensive testing, we are confident that the rigid-body 
binding geometry of our model is roughly accurate and that many of the interface residues 
predicted by our model are the interface residues that will one day be revealed by experiment, 
especially with regards to the GFD NAPP interface residues.  In sum, the available data suggests 
that our DR6-GFD NAPP structural interaction model is, at least at the residue-level, a 
reasonably good model that should prove useful in structure-based antagonist design and in the 
design and analysis of experiments. 
 
Results 
The primary aim of the present study was to construct a theoretical model of the DR6-GFD 
NAPP interaction, an interaction that may have implications for AD.  A DR6-GFD NAPP 
interaction model was constructed using homology modeling, rigid-body docking, energy 
minimization, MM-GB/SA pseudo free energy scoring and empirical free energy scoring.  At 
each step in the computational pipeline, theoretical calculations were compared, to the extent 
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permitted by the available data, with experimental results and independently generated 
theoretical results. 
 
Modeling and evaluating our DR6 homology model and the GFD NAPP crystal structure.  
Figure 1 provides a ribbon representation of the GFD NAPP crystal structure (28-123).  GFD 
NAPP is a high resolution (1.8 Å), high quality (R-value = 0.203; R-free value = 0.242) crystal 
structure that exhibits a globular fold.  Several key residues (66-81) that comprise a lone alpha-
helix-loop motif are highlighted in cyan.  Anti-GFD NAPP antibody 22C11 interacts with the 
alpha-helix-loop motif and blocks DR6-GFD NAPP binding. 
     Figure 2 provides a ribbon representation of our refined DR6 ectodomain homology model.  
The ectodomain of DR6 comprises residues 67-211.  The DR6 ectodomain model takes on a 
more extended shape and exhibits beta secondary structure interconnected through less well 
defined structural elements.  The DR6 structure appears to form a structural depression or basket 
region that seems well suited to accommodate a globular protein such as GFD NAPP.  The DR6 
homology model was evaluated using a variety of computational tools and the results are 
summarized in Table 1.  The DR6 homology model was ultimately docked to the GFD NAPP 
crystal structure. 
 
Modeling the interaction between DR6 homology and GFD NAPP. Figure 3 provides a ribbon 
representation of the final or best DR6-GFD NAPP interaction model.  The model indicates an 
important recognition role for the GFD NAPP alpha-helix-loop motif (residues 66-81).  It also 
appears that the GFD NAPP alpha helix rests in or lines the previously mentioned DR6 structural 
depression or basket.  Worth noting is that the empirically predicted binding affinity implied by 
the docked model (-11.1 kcal/mol) is in excellent agreement with the experimentally estimated 
binding free energy (-11.5 kcal/mol). 
 
Biophysical testing of the DR6-GFD NAPP interaction model. Both NAPP and an N-terminal 
fragment of APLP2 have been shown to bind the DR6 ectodomain.  Given this, we judged it 
worthwhile to align the sequences between GFD NAPP and APLP2.  Figure 4 displays the 
sequence alignment.  Secondary structural information is also presented.  The anti-GFD NAPP 
(22C11) antibody binding epitope is indicated by a solid black line.   
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     The GFD NAPP binding site residues suggested by our docking study were compared to the 
GFD NAPP binding site residues suggested by the experimentally observed inhibitory activity of 
the anti-GFD NAPP 22C11 antibody.  The results are graphically summarized in Figure 5. 
     Nikolaev and co-workers showed that the neurotrophin receptor p75 binds NAPP, albeit with 
lower affinity (EC50 ≈ 300 nM) than does DR6.  Given this, Figure 6 provides the results of a 
pairwise sequence alignment between the DR6 ectodomain and p75.  Also provided in Figure 6 
is secondary structural information for the DR6 ectodomain. 
 
Theoretical testing of the DR6-GFD NAPP interaction model. PPI-Pred was used to predict 
binding patches for GFD NAPP and the ectodomain of DR6.  For GFD NAPP, PPI-Pred 
produced two patches (I and II).  For DR6, PPI-Pred calculated three binding patches (I, II, and 
III).  The results for GFD NAPP are graphically summarized in Figure 5.  Running from left to 
right (a, b, and c) are structural models that depict (in cyan) interface residues derived from the 
22C11 antibody binding experiments, putative GFD NAPP interface residues derived from the 
present docking study, and potential interface residues obtained from the PPI-Pred calculations.  
Only the calculated PPI-Pred residues that agree with the residues obtained from docking study 
are shown.  The results are also summarized in Table 2. 
     As in the case of GFD NAPP, putative DR6 interface residues derived from the docking study 
were compared to potential DR6 interface residues derived from PPI-Pred.  Unlike the case with 
GFD NAPP, an experimentally derived DR6 interface residue set proved to be unavailable.  Only 
the calculated PPI-Pred residues that agree with the residues obtained from docking are shown.  
The results are summarized in Figure 7 and in Table 3. 
 
Discussion 
 
A growing body of evidence implicates trophic factor deprivation, APP metabolism, pro-
apoptotic caspase activity, neuronal apoptosis, and neuronal and neuritic degeneration in AD. 
In a recent article, Nikolaev and colleagues describe a novel interaction between the death cell 
receptor six ectodomain (DR6) and an N-terminal fragment of APP (NAPP).   While their work 
was primarily focused on understanding the biochemical basis of neural development, they 
nonetheless considered the possible implications of their work for AD.  Indeed, the DR6-NAPP 
interaction elucidated by Nikolaev et al. might provide the lynchpin for constructing a coherent 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
54
5.
1 
: P
os
te
d 
15
 J
un
 2
01
0
and satisfying framework for understanding the pathological relationship between trophic factor 
deprivation, APP processing, caspase mediated neuronal apoptosis and degeneration, and AD 
disease progression.   
     According to the developmental model of Nikolaev and colleagues, following trophic factor 
deprivation APP is proteolytically cleaved, resulting in the release of N-terminal amyloid 
precursor protein (NAPP) into the extracellular space.  This is thought to be followed by NAPP 
binding to the death cell receptor six (DR6) ectodomain (67-211), resulting in neuronal apoptosis 
and neuronal and axonal degeneration through the downstream mediation of caspase-3 and 
caspase-6.  It is through this mechanism that neuronal connections are pruned and sculpted 
during development.  It is speculated that this pathway is high jacked in the AD brain.      
     Despite its obvious importance, the structural details that characterize the DR6-NAPP 
interactions are unclear.  In an effort to elucidate some of those structural details, we labored to 
produce a theoretical model of the DR6-NAPP interaction through the use of homology 
modeling, rigid-body docking, implicit solvent energy optimization and theoretical free energy 
scoring.  Such a structural model would greatly aid with the design and interpretation of 
experiments and with future structure-based drug discovery efforts. 
     Nikolaev et al. performed binding experiments which indicate that NAPP binds DR6 with low 
nanomolar affinity (EC50 ≈ 4.6 nM or ΔGbind,exp ≈ -11.5 kcal/mol).  Additional biophysical 
evidence presented by Nikolaev et al. strongly suggests that the growth factor domain (GFD) of 
NAPP (GFD NAPP) is the primary DR6 ectodomain interaction partner.  In particular, the fact 
that the GFD NAPP antibody 22C11 blocks NAPP binding to DR6 provides near conclusive 
evidence that GFD NAPP provides the primary or even exclusive interaction surface for the 
DR6-NAPP interaction.  Importantly, a high resolution crystal structure of GFD NAPP (28-123) 
is available.  Unfortunately, a DR6 ectodomain structure is lacking.  Nevertheless, we were able 
to make progress towards our ultimate goal by constructing an optimized DR6 homology model.  
The optimized DR6 ectodomain model was subsequently docked to the GFD NAPP crystal 
structure and the best docked model was selected according to an empirical estimate of the 
binding affinity.  The best docked DR6-GFD NAPP model was then compared against the 
available biophysical data and independently generated theoretical data.  The balance of the 
evidence suggests that our DR6-GFD NAPP model captures the essential structural details of 
DR6 binding to NAPP, especially with regard to the residue-level contribution of GFD NAPP. 
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 The  GFD NAPP crystal structure and the accuracy of our DR6 homology model. The primary 
goal of the present study was to construct a structural model of the interaction between the DR6 
ectodomain and the growth factor-like domain (GFD) of NAPP.  Our first task, then, was to 
obtain structural models of the DR6 ectodomain and GFD NAPP, respectively.  Our second task 
was to verify the physical soundness and accuracy of the structures. 
     We were able to locate a high resolution (1.8 Å) crystal structure of GFD NAPP that included 
residues 23-128.  The excellent R-value (0.203), R-free value (0.242) and unblemished 
Ramachandran plot (data not shown) indicate an excellent structure that is eminently suited for 
modeling work.  As indicated in Figure 1, the GFD NAPP structure reveals a predominantly beta 
globular structure with a single, prominent alpha helical-loop segment that spans residues 66-81.  
As discussed below, this alpha helix-loop motif appears to play an important role in GFD NAPP-
DR6 binding and recognition. 
     An experimentally determined DR6 structure is currently unavailable.  Thus, we decided to 
construct a homology model of the DR6 ectodomain using residues 67-211 and the I-TASSER 
modeling server (Figure 2).  Multiple lines of evidence suggest that our I-TASSER DR6 
ectodomain homology model is a reasonably accurate one that is suitable for modeling work. 
     First, the neurotrophin receptor p75 (PDB code: 1sg1, X chain) that served as the template for 
our DR6 ectodomain model is a good template structure.  The 1sg1 crystal structure is a 
reasonably high quality crystal structure with good resolution (2.40 Å) and an acceptable R-value 
(0.245) and R-free value (0.269).  With the exception of Asp112, all non-glycine residues are 
located within the allowed regions of the Ramachandran map (data not shown).  Like DR6, the 
p75 receptor is a member of the tumor necrosis factor (TNF) family.  Importantly, the 1sg1 
crystal structure provides the coordinates of the p75 receptor in complex with its nerve growth 
factor (NGF) ligand and thus represents a binding competent conformation.  Moreover, Nikolaev 
et al. showed that the p75 receptor was the only other TNF receptor tested that formed a stable 
interaction with NAPP (EC50 ≈ 300 nM).  Finally, the ≈ 28% sequence identity between the 
entire DR6 target sequence and the p75 receptor sequence is good and the overall sequence 
coverage includes the entire DR6 ectodomain (67-211).  These structural, biophysical and 
functional considerations strongly suggest that p75 is a good template for constructing a high 
quality structural model of the binding competent conformation of the DR6 ectodomain. 
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     Second, we built our DR6 model using the I-TASSER server, a homology modeling server 
that has been widely employed by the scientific community and that was ranked first in both the 
CASP7 and CASP8 experiments.  The I-TASSER server follows an especially demanding 
computational workflow.  In particular, I-TASSER automatically selects appropriate protein 
template structures and builds a model of the target or query structure (DR6) through a rigorous 
procedure that involves fragment reassembly of aligned regions, ab initio model construction of 
unaligned regions, clustering, energy scoring and optimization of the target structures hydrogen 
bonding network.  These methodological considerations further suggest the physical accuracy 
and reliability of our DR6 ectodomain model. 
     Third, the internal quality checks automatically calculated by the I-TASSER server further 
suggest that our DR6 ectodomain model is an accurate one.  In particular, for the top ranked 
model the I-TASSER server calculates a C-score, a predicted TM-score and a predicted RMSD 
value.  Briefly, the C-score represents a confidence score for estimating the overall quality of a 
model.  Typically, C-score values are in the range of -5 to 2, with a higher value indicative of a 
model with high confidence.  The C-score of our DR6 model is on the higher side of that range 
(1.31) which suggests a high confidence model.  The target TM and RMSD values provide 
quantitative estimates of how much the I-TASSER homology model is predicted to structurally 
deviate from a hypothetical crystal structure.  A TM score > 0.5 indicates a model of correct 
topology and an RMSD < 0.9 would indicate a model that is predicted to be within the 
unavoidable error of a crystal structure.  The TM-score (0.9±0.06) and RMSD value (2.2±1.7) 
calculated for our DR6 model thus indicate a very good model that is well-suited for modeling 
work.  The results of the I-TASSER quality analysis are summarized in Table 1. 
     Fourth, in addition to the internal I-TASSER quality checks we calculated additional quality 
checks using three independent server-based methods (ProSA, Qmean, and DFIRE).  All three 
methods provide independent verification that our DR6 homology model is a reasonably accurate 
one.  The ProSA server calculates an overall z-score that can be used to evaluate the structural 
quality of a computational protein model with respect to crystal structures and NMR structures.  
The Qmean server employs a five-term composite scoring function that includes a torsional 
potential, a pairwise interaction potential, a solvation term, and two terms that quantify the level 
of agreement between predicted secondary structure and residue accessibilities and observed 
model secondary structure and residue accessibilities.  The Qmean server outputs a pseudo 
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energy that can be used to asses model quality; the lower the calculated Qmean score the better.  
DFIRE is an all-atom statistical potential that can be used to assess non-bonded interactions in a 
given protein model.  A pseudo energy for the entire model is provided which reflects the quality 
of the model.  A lower energy indicates a more native-like model.  The results from the ProSA, 
Qmean and DFIRE calculations are provided in Table 1 and clearly indicate that our DR6 
ectodomain model is reasonably accurate and useful for further modeling work and analysis. 
     Finally, we attempted to refine and improve our DR6 model through energy minimization 
with an implicit solvent model.  The problem of refining reasonably good homology models is a 
difficult but important one.  Recent work by Summa, Chopra and Levitt, suggests that energy 
minimization using an all-atom molecular mechanics force field or knowledge-based potential, 
especially when combined with an implicit (GB/SA) solvent model, can be used to improve the 
structural agreement between model structures and crystal structures.  In particular, their work 
suggests that energy minimization combined with an implicit treatment of the solvent can be 
used to hold crystal structures in their native conformations and move decoy structures into 
better agreement with crystallographic ones19-21.  Given this, we energy minimized our DR6 
ectodomain homology model using the Amber99 force field and GB/SA implicit solvent model, 
as implemented in the TINKER molecular modeling package.  Against the backdrop of the 
results of Summa, Chopra and Levitt, the successful convergence of the minimization and the 
extremely low relative conformational free energy (-4564.2 kJ) suggests that the minimization 
resulted in a superior DR6 model.  The results are summarized in Figure 2 and Table 1.  The 
energy minimized DR6 model served as the input receptor structure we used in the DR6-GFD 
NAPP rigid-body docking study to be discussed below. 
 
Building the DR6-GFD NAPP complex model.  The successful construction of a DR6 homology 
model was a means to an end, for our primary goal was to model the interaction between the 
DR6 ectodomain and GFD NAPP.  To do this, we employed rigid-body computational docking 
using the ClusPro server.  The ClusPro docking server was selected because of the long and 
rigorous publication history that underlies its basic methodology, its widespread use by structural 
biologists, and its impressive record of success in the various CAPRI competitions28,29.  
     Following the ClusPro calculations, the top 10 docked models were subject to rigid-body 
energy minimization and scored and ranked according to a pseudo binding free energy that was 
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calculated using a molecular mechanics potential and GB/SA implicit solvent model.  Docked 
complexes with a positive calculated pseudo binding free energy were filtered out and eliminated 
from further consideration.  Work in our lab and by other groups suggests that this protocol or 
similar protocols can result in more accurate complex structures and an enhanced ability to 
identify accurate or native-like protein-protein interactions (our data is unpublished)30,31. 
     The binding affinities of the selected docked models were then estimated using a recently 
described empirical free energy function25-27.  The empirical free energy function we employed 
estimates the binding affinity according to a regression-weighted sum of six physical descriptors.  
The six descriptors include the number of hydrophobic and charged groups that are buried on 
complex formation, the number of buried interface salt bridge and hydrogen bonding 
interactions, the number of side chain torsions that are immobilized on binding and the interface 
void or gap volume.  The function has been exhaustively tested and has been shown to have an 
accuracy of ≈ 1.0 kcal/mol and to be capable of correctly ranking native and native-like binding 
modes with respect to non-native ones.  This hierarchical free energy estimation protocol 
ultimately converged on a single DR6-GFD complex model that was selected as the best model 
of the DR6-GFD NAPP interaction.  The fundamental propriety of our docking procedure is 
strongly suggested by prior validation on the neurotrophin receptor p75-NGF interaction (see 
Supplementary information Figures 1-3, Tables 1-4). 
 
Testing of the DR6-GFD NAPP complex model.  A priori considerations regarding the rigorous 
and systematic nature of our computational modeling and evaluative protocol suggested that our 
final DR6-GFD NAPP model would be a physically reasonable one.  The next step was to test 
the model a posteriori.  In what follows, we divide the testing into two categories: (1) 
biophysical testing of the docked DR6-GFD NAPP model, and (2) theoretical testing of the 
docked model.  The biophysical model testing phase involved binding affinity comparisons, the 
analysis of GFD NAPP and DR6 sequence alignments and a comparative analysis of anti-GFD 
NAPP 22C11 antibody data.  The theoretical model testing phase involved comparisons between 
data derived from our DR6-GFD NAPP model and independently generated computational data. 
 
Biophysical testing of the DR6-GFD NAPP complex model.  An experimentally-based estimate 
of the of binding affinity for the DR6-GFD NAPP interaction agrees almost perfectly with a 
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theoretical estimate of the binding affinity derived from our DR6-GFD NAPP model (Figure 3).  
This counts as impressive evidence that our model interface is a reasonable one.  In particular, 
Nikolaev at al. used an ELISA based technique to experimentally determine the binding affinity 
of the DR6-NAPP interaction (EC50 ≈ 4.6 nM).  This provided us with the opportunity to 
compare the empirically predicted binding affinity implied by our DR6-GFD NAPP model (Eq. 
(1), ΔGbind = -11.1 kcal/mol) with the corresponding experimental quantity (ΔGbind,exp ≈ -11.5 
kcal/mol).  The observed level of agreement between theory and experiment is excellent and 
while it doesn't prove that our model is an accurate one, it nevertheless provides strong 
verification of our model.  The results of this test are all the more impressive given that the same 
empirical free energy function was used to accurately calculate the binding affinity of the p75-
NGF interaction (-11.8 kcal/mol predicted / -12.4 kcal/mol experimental) that served as the 
template for our DR6 homology model (see Supplementary information Table 4). 
     In addition to binding NAPP, Nikolaev et al. also showed that the DR6 ectodomain binds the 
N-terminus of APLP2.  Thus, we compared the predicted interface residues of GFD NAPP, 
derived from our DR6-GFD NAPP model, with the aligned residue positions of APLP2.  On the 
assumption that interface residues tend to be conserved, we reasoned that if the predicted GFD 
NAPP interface residues were accurate they would display good agreement with the aligned 
APLP2 residues.  In summary, the GFD NAPP interface residues predicted by our docked model 
align nicely with the APLP2 residues that probably mediate binding between APLP2 and DR6 
(Figure 4).  This provides indirect evidence that the residue-level contribution of GFD NAPP to 
DR6 binding is captured by our model. 
     Nikolaev et al. also showed that the NAPP antibody 22C11 interferes with DR6-NAPP 
binding.  Importantly, Hilbich et al. showed that the binding epitope recognized by the 22C11 
antibody spans NAPP residues 66-81.  This represents a stretch of residues that are localized 
around the lone helix (66-76) of GFD NAPP.  On the assumption that 22C11 blocks DR6 
binding to NAPP by binding to the same GFD NAPP surface that mediates DR6-GFD NAPP 
binding, we compared the GFD NAPP interface residues derived from our model with the GFD 
NAPP epitope that is known to bind 22C11.  Once again, we reasoned that good agreement 
between the two would tend to verify our model.  Using a 4.5 Å cutoff criterion, the GFD NAPP 
residues that line the DR6-GFD NAPP interface of our model include residues 67, 68, 70, 71, 74, 
78, and 79.  There thus exists excellent agreement between the experimentally determined 22C11 
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epitope and the interface residues of our model.  Thus, the modeled GFD NAPP contribution to 
DR6 binding enjoys further verification and, moreover, focuses attention on the specific role 
played by helix residues 66-76 in DR6-NAPP recognition. 
     In addition to binding DR6, Nikolaev and coworkers also showed that NAPP binds the p75 
receptor, albeit with reduced affinity.  Thus, we attempted to align the p75 sequence with the 
DR6 ectodomain sequence on the assumption that the DR6 and p75 NAPP binding site residues 
are conserved.  Unlike the case with APLP2, however, the DR6 and p75 alignment results, as 
summarized in Figure 6, paint an ambiguous and difficult to interpret picture.  Out of the 24 
residues (96, 98-99, 103-104, 107-108, 110, 120-121, 128, 130-132, 139, 141-142, 158-159, 
162-165, 167) that comprise the DR6 contribution to our model interface, only 5 (21%) are 
identical to the corresponding residues in p75.  This is slightly less than the overall level of 
conservation that characterized the alignment between p75 and DR6 that was used to construct 
the I-TASSER DR6 homology model.  If we include similar residues, the percentage of DR6-p75 
matches increases to 37.5%.  Interpretation of the results is further complicated by various 
nonconservative substitutions.  For example, p75 substitutes an Arg for DR6 Val167 and a 
second Arg for DR6 Asp98.  Such nonconservative substitutions could explain the reduced 
affinity of p75 for NAPP.  These results suggest that the DR6 binding motif is either not strongly 
conserved by p75 or that our DR6 interface residue model predictions are inaccurate.  We think 
the later possibility is unlikely given all of the evidence presented, the relatively weak binding of 
p75, and given that high sequence conservation alone is an imperfect predictor of shared binding 
motifs32. 
 
Theoretical testing of the DR6-GFD NAPP complex model.  Typically, theoretical protein-
protein or protein-ligand structural models are tested against experimental mutation data33.  
Unfortunately, we were not able to locate any such data for the DR6-GFD NAPP interaction.  
Despite this, we were able to generate similar data using an independent computational 
procedure.  Briefly, we used the protein-protein interaction prediction server or PPI-Pred to 
predict binding surfaces and thus potential interface residues for DR6 and GFD NAPP, 
respectively.  We then compared the set of predicted interface residues, generated using PPI-
Pred, with the set of interface residues derived from our model.  We reasoned that good 
agreement between the two independently generated data sets would tend to confirm the basic 
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accuracy of our model (Figure 5, Figure 7, Table 2 and Table 3).  Importantly, we first validated 
the procedure using the known structural interaction between the neurotrophin p75 receptor and 
its nerve growth factor (NGF) ligand (see Supplementary information Figures 1-3, Tables 1-4). 
     In the case of GFD NAPP, PPI-Pred predicated two possible binding patches (I and II); in the 
case of DR6, PPI-Pred predicted three possible binding patches (I, II, and III).  Out of 44 PPI-
Pred predicted residues for GFD NAPP, 15 agree perfectly with interface residues derived from 
the GFD NAPP binding interaction that characterizes our docked model.  The PPI-Pred patch I 
and III predictions for DR6, failed to show any agreement with our docked model.  The 31 PPI-
Pred patch II residue predictions, however, produced 8 residue hits when compared to the DR6 
residues that contribute to the interface of our docked model.  Hence, many of the DR6 and GFD 
NAPP interface residues that characterize our docked model are also independently predicted to 
be interface residues.  This provides still more evidence that our DR6-GFD NAPP interaction 
model, especially regarding the GFD NAPP contribution, is an accurate one.   
 
Conclusion 
AD is a devastating disease with no effective treatments.  Nikolaev and co-workers have 
proposed a biochemical model of AD that plausibly accounts for much of the available data.  
Key to their model is a novel interaction between the death cell receptor six (DR6) ectodomain 
and an N-terminal fragment of amyloid precursor protein (NAPP), with particular emphasis on 
the growth factor like domain of NAPP (GFD NAPP).  The elucidation of the structural basis of 
the DR6-GFD NAPP interaction could pave the way towards improved understanding of AD and 
innovative pharmacological therapies for AD.  Here we describe a computational work flow for 
constructing a structural model of the DR6-GFD NAPP complex.  The work flow adopted 
combined and integrated homology modeling, quantitative homology model testing and 
evaluation, implicit solvent homology model energy minimization, rigid body protein-protein 
docking and refinement, and a hierarchical method of protein-protein binding free energy scoring 
and ranking.  The use of such a comprehensive modeling pipeline strongly suggested that the 
final DR6-GFD NAPP model would be a reasonable one.  Indeed, extensive testing against 
multiple lines of theoretical and experimental evidence strongly suggests that the DR6-GFD 
NAPP model described here is a good one, especially with regards to the residue-level 
contribution of GFD NAPP.  Interestingly, we show that the theoretically predicted binding 
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affinity for the DR6-GFD NAPP interaction is in quantitative agreement with the experimentally 
determined binding affinity.  To the best of our knowledge, this represents a first in the blind 
modeling of a novel protein-protein interaction.  In summary, the DR6-GFD NAPP interaction 
model proposed here satisfactorily accounts for a wide range of disparate evidences and as such, 
should prove helpful in the design and interpretation of in vitro and in silico experiments aimed 
at understanding and modifying the DR6-GFD NAPP and its connection to AD. 
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Figure Legends and Tables 
 
Figure 1:  Ribbon representation of the GFD NAPP crystal structure with key residues highlighted 
in cyan.   
 
The PDB identifier for the structure is 1mwp.  The structure comprises residues 28-123 and was solved at 
1.8 Å resolution; the structure has an R-value = 0.203 and an R-free value = 0.242.  The cyan colored 
alpha helix and loop span residues 66-81 and makes up the known binding epitope for the anti-GFD 
NAPP antibody 22C11.  Importantly, the 22C11 antibody is known to interfere with DR6-GFD NAPP 
binding.  Hence, it is reasonable to assume that the same helix-loop motif makes up a key recognition 
element for DR6-GFD NAPP binding.  Importantly, according to our best docked model GFD NAPP 
residues E67, G68, L70, Q71, Q74, P78, and E79 are all predicted to be interface residues. 
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Figure 2:  Ribbon representation of the refined DR6 ectodomain homology model. 
 
The refined DR6 ectodomain (67-211) homology model was built using the I-TASSER modeling server 
and was subject to energy minimization using a GB/SA implicit solvent model. 
 
Figure 3:  Ribbon representation of and predicted binding affinity for the best DR6-GFD NAPP 
interaction model. 
  
a 
Complex Predicted ΔG (kcal/mol) Experimental ΔG (kcal/mol) 
DR6 - GFD NAPP -11.1 -11.5 
 
b 
 
a) The refined DR6 ectodomain (67-211) homology model was docked to the GFD NAPP crystal structure 
using the rigid-body ClusPro protein-protein docking server.  The model clearly reveals an important 
recognition role for the lone GFD NAPP alpha helix, in good agreement with the 22C11 antibody data 
(see Figure 1 and 4 for more details).  According to our methodology, the top 10 ClusPro models were 
selected for further analysis.  All 10 ClusPro complexes were subject to rigid-body energy minimization 
and scored using a standard MM-GB/SA methodology.  Complexes with negative MM-GB/SA binding free 
energies were then scored using an empirical free energy function.   
b) The ClusPro model with the best empirical binding free energy (most negative predicted binding affinity 
using Eq. (1)) was selected as the best complex model and is displayed above.  The predicted binding 
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affinity (-11.1 kcal/mol) for the best ClusPro model compares favorably with an experimental value for the 
DR6-NAPP binding affinity (-11.5 kcal/mol).  
Figure 4:  Sequence alignment and secondary structure of the growth factor-like domain of human 
N-terminal APP (GFD NAPP) and APLP2.   
 
Disulfide bonds are shown as yellow dash lines, identical residues are depicted in red, conserved 
residues are in blue, and non-conserved residues are colored black.  The alignment was performed via 
the LALIGN server (http://www.ch.embnet.org/software/LALIGN_form.html). 
Both NAPP and an N-terminal fragment of APLP2 have been shown to bind the DR6 ectodomain.  Thus, 
given the reasonable assumption that binding motifs are highly conserved between protein ligands that 
bind to the same receptor, we aligned the two sequences and calculated percent identify and similarity 
scores.  For the global alignment the percent identity and the percent similarity were calculated to be 71% 
and 93%, respectively.  Using the ClusPro predicted interface residues (identified according to a 4.5 Ǻ 
cutoff) for GFD NAPP and the corresponding aligned positions for APLP2, the percent identity and 
similarity were calculated to be 76% and 92%, respectively.  Keeping in mind that such an analysis is 
plagued by uncertainty, the alignment data can be plausibly interpreted in support of our docked DR6-
GFD NAPP model. 
The anti-GFD NAPP (22C11) antibody binding epitope is indicated by a solid black line.  Nikolaev and co-
workers showed that 22C11 blocks the interaction between DR6 and GFD NAPP.  Thus, it is reasonable 
to assume that the DR6-GFD NAPP interaction, at least in part, is mediated by some of the same 
residues that comprise the 22C11 binding epitope.  And, this appears to be the case (see other Figures, 
Tables and text for further details). 
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Figure 5:  Ribbon representations of GFD NAPP along with 22C11, ClusPro predicted, and PPI-
Pred predicted interface residues (highlighted in cyan).   
 
                                                                 
 
 
 
 
                             a                                                   b                                                  c  
Using a crystal structure of GFD NAPP (1mwp) and a homology model of the DR6 ectodomain, we 
constructed a structural model of their interaction using the ClusPro docking server.  We then compared 
the predicted ClusPro interface residues with the binding epitope of the 22C11 anti-GFD NAPP antibody 
that is known to block binding to the DR6 ectodomain.  We also compared the ClusPro residues with 
interface residue predictions generated using the protein-protein interaction prediction server (PPI-Pred).  
In the case of GFD NAPP, PPI-Pred produced two predicted binding patches (I and II).  The above 
displayed residues were derived from both patches; only PPI-Pred residues that agree with the ClusPro 
residues are displayed.  We reasoned that overlap between all three disparate residue sets would tend to 
verify our model; this appears to be the case. 
a). Ribbon representation of GFD NAPP along with the 22C11 antibody binding epitope residues shown 
in cyan as "balls-and-sticks".  
b). Ribbon representation of GFD NAPP along with ClusPro predicted interface residues shown in cyan 
as "balls-and-sticks".  A residue was identified as a ClusPro interface residue according to a 4.5 Ǻ inter-
chain distance criterion. 
c). Ribbon representation of GFD NAPP along with PPI-Pred predicted interface residues shown in cyan 
as "balls-and-sticks".  The PPI-Pred residues were derived from PPI-Pred predicted patches (I and II) and 
only residues that overlap with the ClusPro residues are displayed. 
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Figure 6: Sequence alignment and secondary structure of the human DR6 ectodomain and its 
homolog, p75 (1sg1, chain X).   
 
The alignment was calculated using the LALIGN server.  Disulfide bonds are shown as yellow dashed 
lines, identical residues are depicted in red, conserved residues are shown in blue, and non-conserved 
residues are shown in black.  The basic logic for using the alignment to test our DR6-GFD NAPP protein-
protein interaction model is described in the text and is summarized in Figure 1.  For the global alignment, 
the percent identify was calculated to be 30% and the percent similarity was calculated to be 54%.  For 
the ClusPro predicted interface residues, the values were calculated to be 27% and 36%, respectively.  At 
best, the results of this analysis are inconclusive. 
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Figure 7:  Ribbon representations of the DR6 ectodomain homology model along with ClusPro 
predicted and PPI-Pred predicted interface residues (highlighted in cyan).  
 
 
 
 
 
 
 
 
 
 
 
                                                  a                       b                     c 
See the text and Figure 2 for more details.  The presented data tends to verify our DR6-GFD NAPP 
model. 
a). Ribbon representation of the DR6 ectodomain homology model structure.  The structure was built 
using the I-TASSER modeling server.  Cysteine residues are shown as yellow "balls-and-sticks". 
b). Ribbon representation of the DR6 ectodomain along with ClusPro predicted interface residues colored 
in cyan and depicted as "balls-and-sticks".  
c). Ribbon representation of the DR6 ectodomain along with PPI-Pred predicted interface residues 
colored in cyan and depicted as "balls-and-sticks".  The PPI-Pred residues were derived from PPI-Pred 
predicted patches (I, II and III) and only residues that overlap with the ClusPro residues are displayed. 
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 Table 1: We built a DR6 ectodomain (67-211) homology model using I-TASSER.  The structural and 
physical quality of the I-TASSER model was evaluated using a variety of internal (I-TASSER) and 
external (ProSA, QMEAN, and DFIRE) tools. 
Model Quality DR6-GFD NAPP I-TASSER 
homology model 
I-TASSER C-score* 1.31 
I-TASSER TM-score* 0.9 
I-TASSER RMSD* 2.2 
ProSA Z-Score** -3.87 
QMEAN Score*** 0.445 
DFIRE Energy**** -123.69 
Minimization Energy***** -4564.22 
 
*I-TASSEER server http://zhang.bioinformatics.ku.edu/I-TASSER/ 
**ProSA Server https://prosa.services.came.sbg.ac.at/prosa.php 
***Qmean Server swissmodel.expasy.org/qmean/ 
****http://swissmodel.expasy.org/workspace/ 
*****TINKER GB/SA AMBER99 minimization 
C-score values range from -5 to 2, with a higher value indicative of a good model.  A TM-score > 0.5 is 
associated with a model of correct overall topology.  A calculated RMSD value of 2.2 suggests a model 
with relatively high resolution.  The ProSA, Qmean and DFIRE scores all suggest a high quality model.  
More dtail is available in the text. 
The DR6 model was refined using energy minimization along with the Amber99 force field and GB/SA 
implicit solvent model, as implemented in the TINKER molecular modeling package. 
 
 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
54
5.
1 
: P
os
te
d 
15
 J
un
 2
01
0
 Table 2: Comparisons between three different methods for predicting interface residues for GFD 
NAPP.   
ClusPro predicted interface residues for GFD NAPP: 
C38,G39,T59,K60,T61,C62,I63,D64,T65,E67,G68,L70,Q71,Q74,P78,E79,I82,T83,K99,R100,K103, 
Q104,E121,F122,V123 
PPI-Pred predicted interface residues for GFD NAPP 
C38,G39,T61,C62,I63,D64,T65,Q74,P78,E79,I82,T83,E121,F122,VAL123 
22C11 predicted interface residues for GFD NAPP: 
K66,E67,G68,I69,L70,Q71,Y72,C73,Q74,E75,V76,Y77,P78,E79,L80,Q81 
 
The first row provides the interface residue predictions or contributions of GFD NAPP implied by our DR6-
GFD NAPP ClusPro docked model, using a 4.5 Ǻ inter-chain cutoff criterion.  The residues provided in 
the first row provide the basis for comparison with the bottom two rows.  Residue agreement with the first 
row is thus indicated by underlining residues in the bottom two rows.  Substantial agreement between the 
three independently generated data sets would tend to verify our docked model and this appears to be 
the case.   
The second row provides interface residue predictions for GFD NAPP that were generated using PPI-
Pred.  Only PPI-Pred residues that agree with the ClusPro residues are underlined.  For GFD NAPP, PPI-
Pred predicted two binding patches (I and II).  Patch I has 25 residues; 8 overlap with the ClusPro 
interface residues; the first 8 residues above correspond to patch I.  Patch II has 19 residues; 7 overlap 
with the ClusPro residues; the last 7 residues are from patch II. 
The third row provides interface residue predictions for GFD NAPP that were inferred from the fact that 
(1) the anti-GFD NAPP antibody 22C11 has a known GFD NAPP binding epitope (displayed) and (2) that 
22C11 blocks the interaction between DR6 and GFD NAPP.  Thus, we assume or predict that to block the 
DR6 interaction 22C11 is binding to the very GFD NAPP epitope that, at least in part, mediates binding to 
DR6. 
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 Table 3: Comparisons between two different methods for predicting interface residues for the 
homology model of the DR6 ectodomain.  More details are provided in the text and in Table 1.  The 
good agreement exhibited between the two interface residue data sets tends to verify our DR6-
GFD NAPP docked interaction model. 
ClusPro predicted interface residues for DR6 ectodomain homology model: 
F96,R98,H99,I103,E104,H107,D108,K120,L121,D128,E130,C131,T132,Q139,N141,A142,K158,E162, 
T163,E164,D165,R167  
PPI-Pred predicted interface residues for  DR6 ectodomain homology model 
D108,K120,D128,E130,C131,T132,Q139 
 
PPI-Pred produced three patch predictions for DR6.  Only PPI-Pred predictions that agree with the 
ClusPro residues are underlined.  For DR6, PPI-Pred produced three patch predictions (I, II, and III).  
Patch I is 27 residues, Patch II is 31 residues and patch III is 17 residues.  All of the above displayed PPI-
Pred residue predictions are derived from Patch II. 
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 Methods 
 Recently, Nikolaev and co-workers described a protein-protein interaction between death 
cell receptor 6 (DR6), a transmembrane protein that is a member of the Tumor Necrosis Factor 
(TNF) family of proteins, and the N-terminal domain (1-286) of amyloid precursor protein 
(NAPP).  The DR6-NAPP interaction is of considerable interest as it might play a role in 
Alzheimer's disease (AD) pathogenesis.  Biophysical evidence suggests that the DR6-NAPP 
interaction specifically involves the DR6 ectodomain (67-211) and the growth factor-like domain 
(GFD) of NAPP.  Clearly, a structural model of the DR6-GFD NAPP interaction would prove 
beneficial.  We propose to build such a model through the integrated use of homology modeling, 
rigid-body protein-protein docking, energy minimization and computational binding affinity 
scoring and ranking.  In particular, we constructed and optimized a homology model of the DR6 
ectodomain, docked it to the crystal structure of GFD NAPP (28-123), and used a recently 
described empirical free energy function to select the best DR6-GFD NAPP protein-protein 
interaction model.  During model construction, a number of independent methods were used to 
assess model quality and guide model selection.  The final docked DR6-GFD NAPP model was 
subject to a number of tests against several lines of biophysical and theoretical data. 
 
Building the DR6-GFD NAPP interaction model: computational details 
 Briefly, our modeling work-flow combined crystal structure evaluation (GFD NAPP), 
homology modeling (DR6), and homology model refinement through energy minimization.  In 
an effort to ensure model structural quality, extensive quality tests were performed along the 
way.  Ultimately, we relied on rigid-body protein-protein docking, rigid-body energy 
minimization and computational free energy scoring, to suggest a viable DR6-GFD NAPP 
interaction model for further testing and analysis. 
 
Modeling and evaluating the structure of GFD NAPP.  Rossjohn et al. have solved the crystal 
structure of residues 28-123 of GFD NAPP at 1.8 Å resolution.  The structure is available in the 
Protein Data Bank (PDB) (http://www.pdb.org/pdb/home/home.do) with PDB identifier 1mwp.  
The high quality of the GFD NAPP crystal structure was verified using standard tools.  We used 
the 1mwp structure in the present study and docked it to a homology model of the DR6 
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ectodomain15.  All protein models and pictures were prepared using Swiss PDB Viewer 
(http://spdbv.vital-it.ch/)34. 
 
Modeling the structure of the ectodomain of DR6.  We used the I-TASSER homology modeling 
server (http://zhang.bioinformatics.ku.edu/I-TASSER/) to construct a theoretical model of the 
DR6 ectodomain16-18,22.  Towards that end, we submitted DR6 residues 67-211 to the I-TASSER 
server.  The I-TASSER server builds homology models through an exhaustive process that 
involves automatic template selection, fragment reassembly of aligned regions, ab initio 
modeling of unaligned regions, clustering, energy evaluation and the optimization of a models 
hydrogen bonding network.  Ultimately, we selected the top ranked I-TASSER DR6 model, 
based on the template supplied by the crystal coordinates of the neurotrophin receptor p75 in 
complex with the neurotrophin ligand (PDB code: 1sg1, chain X), for further analysis and 
eventual docking. 
 
Evaluating the quality of the I-TASSER DR6 ectodomain homology model.  Homology model 
construction is typically followed by visual and quantitative model evaluation.  Importantly, the 
I-TASSER server automatically calculates and outputs various quality scores to assist end-users 
in model evaluation and selection.  In particular, I-TASSER calculates an overall target quality 
score and a predicted target TM score and RMSD score.  The quality of our DR6 ectodomain 
homology model was further assessed according to a Ramachandran map analysis and through 
the use of three independent server-based methods: ProSA, Qmean and DFIRE34-38.  The ProSA 
server is available at: https://prosa.services.came.sbg.ac.at/prosa.php.  Qmean and DFIRE were 
accessed through the SWISS-MODEL server (http://swissmodel.expasy.org/).  All three servers use 
disparate methods to calculate quantitative scores that can be used to asses model quality and 
guide model selection. 
 
Refining the structure of the I-TASSER ectodomain DR6 model.  We used energy minimization, 
along with the Amber99 force field and the GB/SA implicit solvent model, to refine our DR6 
ectodomain model.  A termination criterion of 0.5 kcal/mol was applied and convergence was 
achieved.  All calculations were carried out using the TINKER molecular modeling package 
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(http://dasher.wustl.edu/tinker/)39.  The energy minimized I-TASSER DR6 ectodomain 
homology model was then used in the docking study. 
 
Using docking to model the interaction between the ectodomain of DR6 and GFD NAPP.  Our 
primary goal was to generate a reasonably good model of the interaction between the DR6 
ectodomain and GFD NAPP.  To achieve this goal we used the refined I-TASSER DR6 
ectodomain model along with the GFD NAPP crystal structure as inputs to the ClusPro Docking 
server, version 1.0 (http://nrc.bu.edu/cluster/cluspro_v1.cgi)23,24.  By default, the ClusPro server 
docks receptor (DR6) and ligand (GFD NAPP) structures using version 1.0 of the DOT rigid-
body docking algorithm (http://www.sdsc.edu/CCMS/DOT/).  The top 20,000 complexes 
generated by DOT are then filtered according to electrostatic and desolvation energies and the 
top 2,000 complexes are retained for further processing.  The retained 2,000 conformations are 
then clustered according to interface RMSD and the top 10 docked models, following a short 
Charrm19 energy minimization, are made available for download.  The top 10 ClusPro models 
probably capture most of the important rigid-body binding geometries and provide excellent 
starting structures for further refinement and analysis. 
 
Refining, scoring and ranking the docked DR6-GFD models.  Ultimately, we sought to narrow 
the top 10 ClusPro models down to a single physically realistic docked configuration.  To 
accomplish this, the binding affinities of the top 10 ClusPro conformations were estimated in a 
hierarchical fashion.  First, all 10 complexes were relaxed through rigid-body energy 
minimization using the Charmm19 force field.  Next, a pseudo-binding affinity was calculated 
for all 10 models using the Charmm19 molecular-mechanics force field and GB/SA implicit 
solvent model (MM-GB/SA).  All calculations were made using TINKER and default settings.  
Finally, ClusPro generated complexes with negative pseudo-binding affinities were scored using 
a recently described empirical free energy function that is available through CMDBioscience 
(http://www.cmdbioscience.com/)25-27. 
     The CMDBioscience approach to protein-protein and protein-peptide binding free energy 
prediction (ΔGbind) involves the use of a novel, fast, physics-based, empirical free energy 
function.  The function is a six-term, regression-weighted expression and is given by, 
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The first two terms refer to binding induced changes in the total number of solvent exposed 
charged (N-terminal nitrogen atoms, Arg and Lys side chain nitrogen atoms; O-terminal oxygen 
atoms, Asp and Glu side-chain carboxyl oxygen atoms; by default, His is treated as uncharged) 
and hydrophobic atoms (C and S atoms), respectively.  The third and fourth terms refer to the 
total number of hydrogen bonds and the net number (difference between favorable and 
unfavorable charge-charge contacts) of short-range (≤ 4 Ǻ) charge-charge or salt bridge 
interactions across the protein-protein interface.  The contributions of these pairwise interface 
hydrogen bonding and salt bridge interactions are penalized according to the degree of solvent 
exposure, such that if the average solvent exposure is greater than some experimentally derived 
threshold value, energetic penalties are added to Eq. (1).  The final three descriptors, in order, 
refer to the interface gap or void volume, the change in the number of solvent exposed side-chain 
torsions or the total number of side chain torsions buried at the interface, and a constant 
contribution.  Changes in the number of solvent exposed main-chain torsions can also be counted 
for peptide ligands in the case of protein-peptide binding.  Default values were used for each 
descriptor and all other important quantities.  The model complex with the lowest empirical free 
energy score (predicted binding affinity) was ultimately selected as the best DR6-GFP NAPP 
structural interaction model. 
 
Testing the DR6-GFD NAPP interaction model 
The above described computational modeling work flow allowed us to identify a single, 
physically plausible, DR6-GFD NAPP interaction model or predicted complex structure.  
Importantly, our modeling work flow incorporated extensive a priori testing and analysis to 
ensure the fundamental physical reasonableness of our docked model.  Our next task was to test 
and evaluate, a posteriori, the accuracy of the docked model against the available data.  Towards 
that end, we tested our DR6-GFD NAPP model against a variety of biophysical data sets and a 
novel theoretical data set. 
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Testing the DR6-GFD NAPP interaction model against the available biophysical data.  Initial 
biophysical model testing involved a quantitative comparison between the theoretical binding 
affinity calculated from our docked model and an experimentally determined value for the 
binding affinity.  Biophysical model testing also involved the analysis of pairwise sequence 
alignments between GFD NAPP and the N-terminus of APLP2 (Amyloid beta (A4) precursor-
like protein 2), on the one hand, and DR6 and p75, on the other.  The alignments were judged to 
be worth analyzing because Nikolaev and co-workers also showed that an N-terminal fragment 
of APLP2 binds DR6 and p75 binds NAPP.  Finally, in the case of GFD NAPP a comparison 
was made between the GFD NAPP interface residues implied by the docked model with the 
GFD NAPP interface residues suggested by the anti-GFD NAPP 22C11 antibody data. 
 
Testing the DR6-GFD NAPP interaction model against the available theoretical data.   The 
theoretical testing involved a comparison between the interface residues derived from our docked 
model with predicted binding site or interface residues for GFD NAPP and DR6, respectively, 
which were calculated using the protein-protein interaction prediction server (PPI-Pred) 
(http://bmbpcu36.leeds.ac.uk/ppi_pred/)40.  From the coordinates of a monomeric protein 
structure, PPI-Pred typically predicts two or three binding patches or two or three well-defined 
residue patches that serve as protein-protein interaction sites.  As will be discussed below, in the 
case of GFD NAPP PPI-Pred produced two patch predictions (I and II); in the case of the DR6 
ectodomain, three predicted interface patches were generated (I, II and III). 
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